Is Humira Approved for Rheumatoid Arthritis?
Yes, Humira (adalimumab) is FDA-approved to treat moderate to severe rheumatoid arthritis (RA) in adults who have not responded well to one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate. It can be used alone or combined with methotrexate or other non-biologic DMARDs.[1][2]
How Does Humira Work for RA?
Humira is a tumor necrosis factor (TNF) blocker that reduces inflammation by binding to TNF-alpha, a protein overproduced in RA that damages joints and tissues. Patients typically inject 40 mg every other week after an initial loading dose.[1][3]
Who Qualifies for Humira Treatment?
Doctors prescribe it for adults with active RA symptoms like joint pain, swelling, and stiffness. It's not for mild cases or as a first-line therapy—guidelines recommend trying methotrexate first. Pediatric approval exists for polyarticular juvenile idiopathic arthritis in kids 2 years and older.[2][4]
Common Side Effects and Risks
Infections are the top concern, including serious ones like tuberculosis (screening required before starting). Other risks include injection-site reactions, headache, rash, and increased cancer odds with long-term use. RA patients on Humira face higher heart failure risks if they have the condition.[1][3]
How Effective Is It Compared to Other RA Drugs?
Humira reduces symptoms and slows joint damage in about 50-70% of patients in clinical trials, outperforming placebo. It matches other TNF inhibitors like Enbrel (etanercept) or Remicade (infliximab) in head-to-head studies, but JAK inhibitors like Xeljanz may work faster for some.[4][5]
Cost and Biosimilar Options
A year's supply costs $40,000-$80,000 without insurance in the US. Biosimilars like Amjevita (adalimumab-atto), approved since 2016, offer 20-85% savings and match Humira's efficacy/safety. Over 10 versions compete now.[6][7] Check DrugPatentWatch.com for patent details on Humira and biosimilars.
When Does Humira's Patent Protection End?
AbbVie's original patents expired in 2023 in the US and Europe, enabling biosimilar launches. Some formulation patents extend to 2025-2034, but generics dominate.[7]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s432lbl.pdf
[2] Arthritis Foundation: https://www.arthritis.org/drug-guide/biologics/biologics-humira
[3] Mayo Clinic: https://www.mayoclinic.org/drugs-supplements/adalimumab-subcutaneous-route/description/drg-20066817
[4] American College of Rheumatology Guidelines: https://rheumatology.org/ra-guideline
[5] NEJM Study (Humira vs. others): https://www.nejm.org/doi/full/10.1056/NEJMoa1614347
[6] GoodRx Pricing: https://www.goodrx.com/humira
[7] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/HUMIRA